370 related articles for article (PubMed ID: 35628931)
21. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Tichenor MS; Wiener JJM; Rao NL; Bacani GM; Wei J; Pooley Deckhut C; Barbay JK; Kreutter KD; Chang L; Clancy KW; Murrey HE; Wang W; Ahn K; Huber M; Rex E; Coe KJ; Wu J; Rui H; Sepassi K; Gaudiano M; Bekkers M; Cornelissen I; Packman K; Seierstad M; Xiouras C; Bembenek SD; Alexander R; Milligan C; Balasubramanian S; Lebsack AD; Venable JD; Philippar U; Edwards JP; Hirst G
J Med Chem; 2022 Nov; 65(21):14326-14336. PubMed ID: 36314537
[TBL] [Abstract][Full Text] [Related]
22. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.
Estupiñán HY; Berglöf A; Zain R; Smith CIE
Front Cell Dev Biol; 2021; 9():630942. PubMed ID: 33777941
[TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase inhibition for the treatment of allergic disorders.
Lin EV; Suresh RV; Dispenza MC
Ann Allergy Asthma Immunol; 2024 Mar; ():. PubMed ID: 38492772
[TBL] [Abstract][Full Text] [Related]
24. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE; Wales TE; Jayne S; Britton RG; Fulton DB; Engen JR; Dyer MJS; Andreotti AH
bioRxiv; 2023 Dec; ():. PubMed ID: 38187560
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
Owens TD; Brameld KA; Verner EJ; Ton T; Li X; Zhu J; Masjedizadeh MR; Bradshaw JM; Hill RJ; Tam D; Bisconte A; Kim EO; Francesco M; Xing Y; Shu J; Karr D; LaStant J; Finkle D; Loewenstein N; Haberstock-Debic H; Taylor MJ; Nunn P; Langrish CL; Goldstein DM
J Med Chem; 2022 Apr; 65(7):5300-5316. PubMed ID: 35302767
[TBL] [Abstract][Full Text] [Related]
26. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
[TBL] [Abstract][Full Text] [Related]
28. Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases.
Najmi A; Thangavel N; Mohanan AT; Qadri M; Albratty M; Ashraf SE; Saleh SF; Nayeem M; Mohan S
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986499
[TBL] [Abstract][Full Text] [Related]
29. The potential of pirtobrutinib in multiple B-cell malignancies.
Jensen JL; Mato AR; Pena C; Roeker LE; Coombs CC
Ther Adv Hematol; 2022; 13():20406207221101697. PubMed ID: 35747462
[TBL] [Abstract][Full Text] [Related]
30. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
31. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
32. Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
Lorenzo-Vizcaya A; Fasano S; Isenberg DA
Immunotargets Ther; 2020; 9():105-110. PubMed ID: 32582577
[TBL] [Abstract][Full Text] [Related]
33. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
Arneson LC; Carroll KJ; Ruderman EM
Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
Lucas F; Woyach JA
Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
[TBL] [Abstract][Full Text] [Related]
35. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Rhodes JM; Mato AR
Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
[TBL] [Abstract][Full Text] [Related]
36. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
37. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
38. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
39. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
